Organoids were platted as small organoids (4 to 10 cells) and treated for 72 hours with chemotherapy. The PyMT breast tumor and BCBM tumor organoids were treated with 30 nM doxorubicin (Actavis), 50 nM topotecan (Sandoz), 50 nM paclitaxel (Fresenius Kabi), 200 nM elacridar (MedChemExpress, catalog no. 58407), or 1 μM Ko134 (Sigma-Aldrich, catalog no. K2144-1MG). The KB1P breast tumor and BCBM tumor organoids were treated with 10 nM doxorubicin (Actavis), 20 nM topotecan (Sandoz), 20 nM paclitaxel (Fresenius Kabi), or 200 nM elacridar (MedChemExpress, catalog no. 58407).
Uceda-Castro R., Margarido A.S., Song J.Y., de Gooijer M.C., Messal H.A., Chambers C.R., Nobis M., Çitirikkaya C.H., Hahn K., Seinstra D., Herrmann D., Timpson P., Wesseling P., van Tellingen O., Vennin C, & van Rheenen J. (2023). BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis. Science Advances, 9(42), eabp9530.
+ Open protocol